Analytical Sciences

Determination of N-Ethylglycine in Urine of Cancer Patients with Metastatic Bone Disease by HPLC Using 4-(5,6-Dimethoxy-2-phthalimidinyl)-2-methoxyphenylsulfonyl Chloride as a Fluorescent Labeling Reagent

Yasuto TSURUTA,* Maya MATSUMOTO,* Hirofumi INOUE,* Sayaka MUNEMURA,* Shigeru YAMANO,** and Haruo IGUCHI***

*Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama, Hiroshima 729-0292, Japan
**Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan, Fukuoka 814-0180, Japan
***Institute for Clinical Research, Shikoku Cancer Center, Horinouchi, Matsuyama, Ehime 790-0007, Japan

A simple and highly sensitive HPLC for the determination of N-ethylglycine in urine was developed. The labeling reaction of N-ethylglycine with 4-(5,6-dimethoxy-2-phthalimidinyl)-2-methoxyphenylsulfonyl chloride was carried out at 70°C for 15 min at pH 9.0. The fluorescent derivative was separated on a reversed-phase column and detected at excitation and emission wavelengths of 320 and 400 nm, respectively. The detection limit of N-ethylglycine was 15 fmol (S/N = 3). The recovery of N-ethylglycine added to urine was 101.9%. The concentration of N-ethylglycine in urine of cancer patients with metastatic bone disease was 11.3 ± 22.0 nmol/mg creatinine, and that of normal subject was 0.4 ± 0.4 nmol/mg creatinine.

J-STAGE: View this article in J-STAGE